Prescient Therapeutics AusBiotech’s Investment Conference Presentation

On October 26, 2021 Prescient Therapeutics (ASX: PTX) CEO Steven Yatomi-Clarke reported at the AusBiotech Investment Conference 2021 (Press release, Prescient Therapeutics, OCT 26, 2021, https://prescienttherapeutics.investorportal.com.au/2021/09/20/prescient-therapeutics-ausbiotechs-investment-conference-presentation?utm_source=rss&utm_medium=rss&utm_campaign=prescient-therapeutics-ausbiotechs-investment-conference-presentation [SID1234591957]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Steven introduced Prescient Therapeutics to a new range of investors, touching on results of the recent PTX100 study and explaining our next-gen CAR-T platform, OmniCAR.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!